Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets